Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mito-LUTS: MitoQ for Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
NCT06351683Phase 2Terminated
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lower urinary tract symptoms (LUTS) and overactive bladder syndrome (OAB) comparing MitoQ group with Placebo Control group (2 arms). Primary endpoint: Overactive Bladder Symptom Score at 16 weeks. Started Apr 2024; status: terminated.
02
Drugs
mitoquinone
03
Conditions
lower urinary tract symptoms (LUTS)overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT06351683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06351683.